01/26/2015 - 3:12pm

The Food and Drug Administration last week announced approval for Bexsero, a vaccine intended to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroup B in individuals 10 years through 25 years of age.

 

01/26/2015 - 3:09pm

The Food and Drug Administration last week approved Natpara (parathyroid horomone), which is indicated to control low blood calcium levels in patients who have hypoparathyroidism.

 

01/26/2015 - 11:59am

Purdue Pharma on Monday announced the launch of Hysingla ER (hydrocodone bitartrate) extended-release tablets CII. According to the company, the once-daily drug is the first and only hydocodone product to be recognized by the Food and Drug Administration as having properties that deter misuse and abuse via chewing, snorting and injection.

01/22/2015 - 12:44pm

The global therapeutics market for Irritable Bowel Syndrome is set to rise in value from $589.6 million in 2013 to $1.5 billion by 2023, representing a high compound annual growth rate of almost 9.9%, according to a report published Thursday by research and consulting firm GlobalData.

01/21/2015 - 3:23pm

Eisai on Tuesday announced the launch of a new savings card for Belviq (lorcaserin HCl) CIV, the most-prescribed branded FDA-approved prescription drug therapy for chronic weight management.

01/21/2015 - 2:52pm

The Food and Drug Administration on Wednesday announced approval for Cosentyx (secukinumab), indicated for the treatment of adults with moderate to severe plaque psoriasis.

 

01/21/2015 - 12:50pm

With specialty and biotech drugs claiming an ever-greater share of the pharmaceutical market and spawning a backlash from payers and patients over their high price tags, pharmacy operators are smack in the middle of a growing tug of war between the drug industry, the public and private health plans struggling to keep up with the new drug-cost paradigm.

01/21/2015 - 12:26pm

Boehringer Ingelheim Pharmaceuticals on Wednesday announced that its Spiriva Respimat (tiotropium bromide) inhalation spray is now available by prescription through pharmacies across the United States. 

 

01/20/2015 - 12:44pm

Teva Pharmaceutical on Tuesday announced the U.S. Supreme Court’s decision in Teva Pharmaceuticals USA vs. Sandoz et al. that reversed the Federal Circuit Court’s judgment of invalidity of Teva’s ‘808 patent for Copaxone (glatiramer acetate injection) 20 mg/mL.